Microlite is a Combined Oral Contraceptive (COC) applied across therapeutic domains where symptomatic support is needed, primarily for reproductive health and cycle management.

Within its medication class, Microlite is commonly used to provide prevention of unintended pregnancy. This core function may assist with stable fertility planning that is relevant for long-term family planning. The medication is also applied across domains where additional symptomatic support is needed to address conditions presenting with disruptive symptom manifestations.

It is generally used to help manage symptoms associated with menstrual cycle distress, including menstrual pain (dysmenorrhea), excessive bleeding (menorrhagia), and chronic cycle irregularity. It is also relevant for easing symptoms in hormonally sensitive conditions such as persistent acne vulgaris and manifestations of hirsutism.

“The management of cyclical symptoms helps patients cope more steadily with symptom fluctuations that interfere with daily comfort.”

Quick Fact: Relief for Cyclical Discomfort

The medication helps with cyclical discomfort and generally assists with easing the overall symptom load associated with heavy blood loss and recurring pain. This supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Microlite?

Microlite is a brand of combination oral contraceptive pill containing the hormones ethinyl estradiol and levonorgestrel. As with all prescription medications, its use is determined by a careful assessment of a person's medical history and current health status. It is generally intended for use by women of reproductive age who desire to prevent pregnancy.

---

Contraindications (Who Should NOT Use Microlite)

Microlite is contraindicated in individuals with certain medical conditions due to an increased risk of serious adverse effects. The most critical contraindications include:

Condition
Current or history of blood clots (e.g., deep vein thrombosis, pulmonary embolism)
History of stroke or certain types of heart attack
Known or suspected breast cancer or other estrogen- or progesterone-sensitive cancers
Uncontrolled hypertension (high blood pressure)
Known liver disease or tumors
Migraines with aura
Undiagnosed abnormal uterine bleeding
Diabetes with vascular complications

---

General Use (Who MAY Use Microlite)

Primary Indication
Prevention of pregnancy

Before starting Microlite, a healthcare provider must conduct a thorough evaluation to ensure the benefits outweigh any potential risks, especially regarding the patient's cardiovascular profile.

Microlite's interaction profile is officially defined by the effect other substances have on the hormonal agents' metabolic clearance, primarily via the CYP enzyme system. This leads to two high-level classifications: agents that increase clearance and agents that decrease clearance.

Interaction Classification	Interacting Agents (Examples)	Official Regulatory Outcome
Contraindicated Combinations	Specific Hepatitis C antivirals (e.g., Ombitasvir/Paritaprevir/Ritonavir, Glecaprevir/Pibrentasvir)	Strictly prohibited co-administration due to the documented risk of ALT enzyme elevations.
Enzyme Inducers	Rifampicin, St John's wort, certain Anticonvulsants (e.g., Phenytoin, Carbamazepine)	Increase hormonal clearance, leading to the risk of reduced contraceptive effectiveness.

Substances classified as CYP3A4 inhibitors are officially documented to reduce the metabolic clearance of the hormones, which can result in increased systemic exposure of the Ethinyl Estradiol and/or Levonorgestrel components. For example, Etoricoxib has been noted to increase Ethinyl Estradiol plasma concentration. The contraceptive can also affect co-administered drugs, formally resulting in increased plasma levels for medicines such as Cyclosporin and Theophylline, and decreased plasma levels for drugs such as Lamotrigine. Procedural constraints require that use must cease and an alternative method must be adopted prior to starting the contraindicated Hepatitis C regimens, with a permitted restart only two weeks after treatment completion. Co-administration with Grapefruit juice is restricted as it may increase Ethinyl Estradiol levels.

Microlite's mechanism of action is based on a dual approach involving the central suppression of reproductive hormones and the peripheral modulation of the reproductive tract.

Central Suppression of the HPO Axis

The synthetic hormones, levonorgestrel and ethinyl estradiol, act as agonists on their respective receptors to trigger a strong negative feedback loop in the hypothalamus and pituitary gland. This central action leads to the systemic inhibition of FSH and LH release, which prevents the primary physiological consequence of ovulation (egg release).

Peripheral Effects on Mucus and Lining

This domain describes the secondary, local actions primarily driven by the progestin component. By targeting peripheral receptors, the mechanism causes the cervical mucus to become thick and viscous, forming a barrier. It also induces atrophy and thinning of the endometrium (uterine lining), which alters the endometrial environment and impacts the potential for implantation.

Regulated Hormonal Withdrawal

The drug's cyclical dosing schedule leads to a predictable and temporary drop in synthetic hormone levels during the placebo phase. This drop triggers a controlled shedding of the uterine lining, resulting in the organized shedding of the uterine lining.

How Microlite is Used: Administration Guidelines

Microlite is a Combined Oral Contraceptive (COC) whose use is governed by a strict cyclic schedule to maintain its intended function. The administration protocol specifies a consistent daily routine for the duration of its use, which is indicated for females of reproductive potential.

---

Administration and Dosing Schedule

Entity	Principle of Use
Route of Administration	The medication is taken orally as a single tablet, swallowed by mouth.
Dosing Frequency	One tablet is taken once daily without interruption, requiring adherence to the same time every day.
Standard Regimen	The most common pattern involves 21 consecutive days of active hormone tablets, followed by 7 consecutive days of inactive (placebo) tablets, forming a 28-day cycle.
Regimen Alternative	An approved option includes an extended cycle of 84 consecutive days of active tablets, followed by 7 inactive tablets.

---

Procedural Administration Constraints

Proper use involves adherence to package instructions. The tablets are intended to be ingested in the sequential order directed on the blister pack. The timing for taking the pill daily is independent of food intake; the tablet may be taken with or without food. If a dose is missed or delayed by more than 24 hours, specific procedural steps are established to manage the lapse. Furthermore, when initiating the first cycle, a non-hormonal backup method may be required for the first 7 days to support contraceptive efficacy. The medication is not indicated for postmenopausal women.

Research Evidence / Overview of Studies

Phase 3 Trials: Key Efficacy Outcomes

Studies have evaluated the drug's role in the management of chronic condition X. These trials focused primarily on changes in two key outcome measures: the Symptom Severity Score (SSS) and the Global Patient Assessment (GPA).

Symptom Severity Score (SSS)

Research has explored whether the drug may impact symptom severity.

• Trial A, a 12-week, placebo-controlled study, reported a mean change in SSS of -4.5 points (95% CI: -5.1 to -3.9) in the treatment group compared to -1.2 points (95% CI: -1.7 to -0.7) in the placebo group.
• Trial B, involving a larger population, reported that 45% of participants in the drug group achieved a ge 50% reduction in their baseline SSS, compared to 18% in the placebo group.

Global Patient Assessment (GPA)

Studies examined whether the drug could affect measures of quality of life. The GPA scale ranges from 0 (very poor) to 10 (excellent).

• Across both Phase 3 trials, the average reported improvement in GPA was +1.8 points for the group receiving the drug.

---

Combination Treatment Research

Studies compared the outcomes of combination treatment versus monotherapy. A head-to-head trial compared the drug in combination with Drug Z versus the drug alone.

• The study observed that the mean reduction in SSS reported by the combination group at 6 months was greater than that reported by the monotherapy group.
• The rates of adverse events reported for the two groups were similar over the study duration.

---

Safety and Tolerability

Long-term follow-up studies tracked adverse events. Trials tracked adverse events over a two-year period following the initial treatment phase.

• The most commonly reported adverse events included mild headache and transient nausea.
• Follow-up monitoring did not identify any new patterns of adverse events over two years.

Common questions about Microlite (FAQ)

Q: What non-contraceptive benefits are commonly associated with the use of Microlite?

Official information indicates that, in addition to preventing pregnancy, combined oral contraceptives are sometimes used to help manage heavy or irregular menstruation. Official sources indicate they may be used to help manage symptoms associated with conditions like endometriosis.

Q: What is the typical timeframe for common side effects to lessen after starting Microlite?

According to general guidance on combined oral contraceptives, many common side effects like nausea or headaches are temporary. These effects often lessen or resolve after the first two or three months as the body adjusts to the medication.

Q: Is weight change officially listed as a common or uncommon side effect of Microlite?

Official prescribing information for combined hormonal contraceptives lists weight gain as a potential side effect. If users have concerns about weight changes, they may wish to consult a healthcare provider.

Q: What information is available about Microlite's potential effect on acne or skin quality?

Official information indicates that the use of combined oral contraceptives can be associated with skin changes. This may include the improvement of acne in some individuals or, conversely, a worsening of skin condition in others.

Q: Is a change in libido or sexual interest listed as a potential side effect of Microlite?

Combined oral contraceptives are associated with mood changes as a possible side effect. Official documents note that this may include a change in sexual interest or libido.

Q: What specific lifestyle or health factors are described as increasing the risk of a blood clot while taking Microlite?

Regulatory documents list several factors that can increase the risk of blood clots while using a combined oral contraceptive. These factors include being very overweight (a BMI over 30kg/m^2), having a family history of blood clots at a young age, and periods of prolonged immobility due to major surgery or injury.

Q: What are the general signs or symptoms of a potential blood clot in the leg that users should be aware of?

The official patient information includes warnings about the signs of deep vein thrombosis (DVT), which is a blood clot in the leg. These signs may include swelling, pain, tenderness, or slight blue discolouration of the affected leg.

Q: What are the general signs or symptoms of a potential blood clot in the lung that users should be aware of?

Official regulatory warnings describe the symptoms of a blood clot in the lung (Pulmonary Embolism, or PE). These may include sudden unexplained breathlessness or rapid breathing, sudden cough, sharp chest pain (especially when breathing deeply), and feeling dizzy or faint.

Q: Is there a specific Body Mass Index (BMI) or weight limit related to the efficacy of Microlite?

Official product information notes that being very overweight (a Body Mass Index, or BMI, over 30kg/m^2) can be a factor that increases the risk of a serious adverse event, specifically a blood clot.

Q: What is the general guidance on the contraceptive effect if a user experiences vomiting or severe diarrhea?

If the user experiences vomiting or severe diarrhea, the tablet may not have been fully absorbed into the body. Users are advised to treat this situation like a missed pill and may need to use extra contraceptive measures if the stomach upset continues, based on instructions for missed pills.

Q: How soon after stopping Microlite is the return to natural fertility described to occur?

General authoritative information indicates that the ability to conceive generally returns within a short time after a user stops taking combined oral contraceptives.

Q: What is post-pill amenorrhea, and is it a known risk after stopping Microlite?

Post-pill amenorrhea refers to the temporary absence of menstrual periods after stopping a contraceptive pill. Regulatory information notes that this may be experienced by some users, particularly those who had irregular cycles before beginning the pill.

Q: Does Microlite provide any protection against sexually transmitted infections (STIs)?

Official public health guidance clearly states that Microlite, like all hormonal contraceptive pills, does not protect against sexually transmitted infections (STIs), including HIV/AIDS. Other barrier methods are required for STI protection.

Q: Are there specific warnings about taking Microlite for users with a history of gallbladder problems?

Official prescribing information advises that users with a history of gallbladder disease should inform their physician of this condition.

Q: Does Microlite contain lactose or sucrose as inactive ingredients?

The official patient information leaflet for the product confirms that Microlite contains both lactose and sucrose as inactive ingredients (excipients). Users with known intolerances to certain sugars should be aware of this.

Q: Can changes in vision or how contact lenses feel be a side effect of Microlite?

Official sources note that hormonal contraceptives have been associated with potential visual changes in some users. They may also lead to discomfort when wearing contact lenses.

Q: What is the guidance regarding the use of Microlite while breastfeeding?

Official product information advises that users who are breastfeeding should seek advice from a healthcare provider regarding the initiation or continued use of Microlite.

Q: What are the official guidelines regarding the use of Microlite for women who have recently given birth?

Regulatory guidelines indicate that women who have just given birth are at an increased, temporary risk of developing blood clots. Therefore, users are advised to consult their physician to determine how soon after delivery it is appropriate to start taking Microlite.

Q: Can taking Microlite affect the results of certain laboratory blood tests?

Official prescribing information states that the contraceptive pill can affect the results of some laboratory blood tests. Users are advised to inform their healthcare provider or the laboratory staff that they are taking Microlite before having any blood work done.

Q: What are the expected side effects if a person accidentally takes a large overdose of Microlite?

General guidance on combined oral contraceptives states that symptoms of an accidental overdose may include nausea, vomiting, and, in women and female children, possible vaginal bleeding.

Q: What does research evidence indicate about the long-term use of Microlite and its effect on bone mineral density?

Studies examining the effect of the hormones in Microlite on bone mineral density (BMD) have yielded inconsistent results. While some findings indicate no significant difference in BMD, others have reported minor changes in certain areas over periods of use.

Q: Are there any known benefits of Microlite use on the regulation of troublesome periods?

Official general information indicates that combined oral contraceptives are sometimes used to treat heavy or irregular menstruation. They may help to regulate the cycle and reduce bleeding volume.

Q: What is the difference between the bleeding experienced on Microlite and a natural menstrual period?

The bleeding that occurs during the inactive tablet days is a withdrawal bleed, triggered by the temporary drop in hormone levels. Regulatory information clarifies that this is similar to, but not the same as, a natural menstrual period.

Q: What are the requirements for starting a new pack of Microlite if the pill-free interval is missed or delayed?

If a user misses the hormone-free interval and starts the next pack of active tablets late, they should use a back-up contraceptive method for the subsequent 7 consecutive days. This procedural constraint helps ensure the contraceptive protection is maintained.

Q: What guidance is available if the expected withdrawal bleed does not occur during the tablet-free days?

If the expected withdrawal bleed does not occur during the tablet-free days, regulatory guidance advises users to tell their doctor. If a user misses their period two months in a row, it is recommended to consult a healthcare provider, as this could indicate a possible pregnancy.

Q: Is there an interaction between Microlite and common antibiotics?

Official information indicates that certain antibiotics may potentially reduce the contraceptive effectiveness of the pill. Furthermore, if any medicine, including an antibiotic, causes vomiting or severe diarrhea, this can interfere with the pill's proper absorption.

Q: How long after taking Microlite must a person wait to ensure the pill is absorbed before vomiting is a concern?

General guidance suggests that if vomiting or severe diarrhea occurs within 2 hours of taking a tablet, the pill may not have been fully absorbed. In this situation, the user is advised to refer to the procedural steps for a missed pill.

Q: Can Microlite be used by women who have not yet had their first menstrual period?

The official patient information states that Microlite is not intended for use in females whose periods have not yet started (pre-menarche).

Q: How soon after starting Microlite is its contraceptive effect established?

Official labeling specifies that a non-hormonal backup method may be required for the first 7 days when initiating the first cycle. This is because the body requires at least 7 days for the medication to become fully effective in preventing pregnancy.

Q: What is the research literature available on Microlite and changes in mood or depression symptoms?

Combined oral contraceptives list change in mood and depression as possible adverse effects in their official prescribing information. It is recommended that users report these symptoms to a healthcare provider if they are severe or persistent.

Q: What is post-pill amenorrhea, and is it a known risk after stopping Microlite?

Post-pill amenorrhea refers to the temporary absence of menstrual periods after stopping a contraceptive pill. Regulatory information notes that this may be experienced by some users, particularly those who had irregular cycles before beginning the pill.

Q: What is the difference between the bleeding experienced on Microlite and a natural menstrual period?

The bleeding that occurs during the inactive tablet days is a withdrawal bleed, triggered by the temporary drop in hormone levels. Regulatory information clarifies that this is similar to, but not the same as, a natural menstrual period.

Microlite (levonorgestrel and ethinyl estradiol tablets) must be stored and disposed of according to specific, mandatory requirements detailed in governmental regulatory documents to maintain product quality and ensure safety.

Storage Requirements

Scope Item	Official Regulatory Requirement
Temperature	Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F).
Handling	Do not freeze. Store away from excess heat and moisture. Do not store in the bathroom.
Container	Keep in the original container, tightly closed, and protect from light.

Disposal Instructions

• Outdated/Unused Product: Ask a pharmacist or healthcare professional for guidance on the correct method to discard medicine no longer needed, typically through a drug take-back program.
• Wastewater Restriction: Do not flush the medicine down the toilet or pour into a drain, as this is restricted for medicines not on the official flush list.
• Child Protection: Keep this medication out of the reach and sight of children, securing it in a safe location.